Bionano Genomics Inc
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It als… Read more
Bionano Genomics Inc (BNGO) - Total Assets
Latest total assets as of September 2025: $79.06 Million USD
Based on the latest financial reports, Bionano Genomics Inc (BNGO) holds total assets worth $79.06 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bionano Genomics Inc - Total Assets Trend (2016–2024)
This chart illustrates how Bionano Genomics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bionano Genomics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Bionano Genomics Inc's total assets of $79.06 Million consist of 51.5% current assets and 48.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.0% |
| Accounts Receivable | $4.77 Million | 6.2% |
| Inventory | $11.12 Million | 14.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.71 Million | 12.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Bionano Genomics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bionano Genomics Inc's current assets represent 51.5% of total assets in 2024, a decrease from 72.6% in 2016.
- Cash Position: Cash and equivalents constituted 12.0% of total assets in 2024, down from 35.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 14.5% of total assets.
Bionano Genomics Inc Competitors by Total Assets
Key competitors of Bionano Genomics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
|
LKL International Bhd
KLSE:0182
|
Malaysia | RM173.46 Million |
Bionano Genomics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bionano Genomics Inc generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bionano Genomics Inc is currently not profitable relative to its asset base.
Bionano Genomics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.12 | 1.43 | 5.23 |
| Quick Ratio | 1.82 | 0.99 | 4.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $25.82 Million | $ 14.03 Million | $ 37.85 Million |
Bionano Genomics Inc - Advanced Valuation Insights
This section examines the relationship between Bionano Genomics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.24 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -64.2% |
| Total Assets | $76.67 Million |
| Market Capitalization | $9.63 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bionano Genomics Inc's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bionano Genomics Inc's assets decreased by 64.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bionano Genomics Inc (2016–2024)
The table below shows the annual total assets of Bionano Genomics Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $76.67 Million | -64.24% |
| 2023-12-31 | $214.40 Million | -30.28% |
| 2022-12-31 | $307.50 Million | -18.46% |
| 2021-12-31 | $377.10 Million | +523.83% |
| 2020-12-31 | $60.45 Million | +100.11% |
| 2019-12-31 | $30.21 Million | +21.79% |
| 2018-12-31 | $24.80 Million | +144.48% |
| 2017-12-31 | $10.15 Million | -31.39% |
| 2016-12-31 | $14.79 Million | -- |